Ascendis Pharma A/S (NASDAQ:ASND) has been assigned an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.

Brokers have set a one year consensus price objective of $30.67 for the company and are expecting that the company will post ($0.71) EPS for the current quarter, according to Zacks. Zacks has also given Ascendis Pharma A/S an industry rank of 107 out of 265 based on the ratings given to its competitors.

ASND has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a report on Monday, August 15th. Wedbush assumed coverage on shares of Ascendis Pharma A/S in a research report on Monday, September 26th. They issued an “outperform” rating and a $34.00 price target on the stock. TheStreet upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Finally, Leerink Swann reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Friday, September 2nd.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Ascendis Pharma A/S (NASDAQ:ASND) traded down 0.40% during trading on Thursday, hitting $19.91. The company had a trading volume of 3,425 shares. Ascendis Pharma A/S has a 52-week low of $11.92 and a 52-week high of $21.70. The firm’s 50 day moving average is $19.64 and its 200-day moving average is $16.26. The stock’s market capitalization is $501.59 million.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, August 31st. The company reported ($0.59) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.10. Ascendis Pharma A/S had a negative net margin of 818.32% and a negative return on equity of 47.61%. On average, equities analysts forecast that Ascendis Pharma A/S will post ($3.14) earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

5 Day Chart for NASDAQ:ASND

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with's FREE daily email newsletter.